This lecture explains the pharmaceutical drug development pathway, from early research decisions to regulatory approval with a focus on the following topics:
- How a scientific discovery becomes an approved medicine
- Key stages of pharmaceutical drug development, explained clearly
- What regulators expect and why it matters early
- Common mistakes that slow down or stop promising programs
- Practical guidance for academics and startups moving toward the clinic
?
Speakers
Get valuable insights from two highly experienced experts from the Norwegian Medical Product Agency (DMP).
Ingvild Aal?kken
Special advisor DMP
Ingvild is an experienced life science professional with 20+ years experience from the regulatory authorities.
She also has a background from pharmaceutical industry holding positions in Astra and Astra Zeneca.
Ingvild holds an MSc in dentistry from the University of Oslo.
?
Rune Kjeken?
Scientific Director - Advanced Therapies, DMP
Rune has a profound expertise in advanced therapy medicinal products (ATMPs), bridging innovation, clinical development, and regulatory science.
Before joining DMP in 2009, he was for several years the Executive Director, Research & Development at Inovio Biomedical Corporation.
Rune holds a PhD in Molecular Biology from the University of Oslo.
?
SPARK Norway Educational Forum are monthly open meetings organized by UiO:Life Science and SPARK Norway partners.